Coagulation Cascade: Extrinsic/Intrinsic Pathways and Fibrinolysis
Coagulation cascade (serine protease amplification; two initiation pathways converging on common pathway at FXa/FVa prothrombinase complex): extrinsic pathway (primary physiological initiator; TF (tissue factor/CD142/F3; transmembrane; exposed on sub-endothelial cells/activated endothelium/monocytes; TF-FVIIa complex (extrinsic Xase); TF–FVIIa → FX → FXa (extrinsic) + FIX → FIXa (intrinsic amplification); TF Cys186–Cys209 disulphide; cytoplasmic Cys245 palmitoylation; NF-κB drives TF expression in inflammation)); intrinsic pathway (contact activation; FXII–PK–HMWK → FXIIa → FXIa → FIXa + FVIIIa (intrinsic Xase complex) → FXa); common pathway: FXa + FVa (prothrombinase complex; phosphatidylserine-rich platelet surface; Mg2+; FVa Lys994 APC cleavage site; prothrombinase → prothrombin (FII) Arg271/Arg320 → thrombin (FIIa; Ser195/His57/Asp102 catalytic triad)); thrombin (FIIa; serine protease; fibrinogen (Fb; soluble; AαBβγ chains ×2; FpA/FpB cleavage → fibrin monomer → lateral/longitudinal assembly → fibrin polymer); FXIII → FXIIIa (thrombin-activated; ε-amino isopeptide cross-links; γ-dimer → fibrin clot; α2-AP incorporation → plasmin resistance)); natural anticoagulants: (1) antithrombin III (ATIII/SERPINC1; thrombin/FXa/FIXa; Lys114/Arg393 reactive centre loop; heparin-accelerated (×1000); Cys247–Cys430 disulphide); (2) protein C/S/thrombomodulin (PC: TM-thrombin → APC (activated protein C) → FVa Lys994/Arg506/Arg306 cleavage → FVa ↓; FVIIIa ↓; EPCR (endothelial PC receptor) → APC; PS (protein S; FVa-APC cofactor; vitamin K-dependent); TM (thrombomodulin; endothelial; Cys residues; NF-κB suppressed; eNOS-NO ↑ TM expression)); fibrinolysis: tPA (tissue plasminogen activator; Ser-Pro active site; fibrin-stimulated (fibrin kringle domains → tPA Km ↓ 300-fold); tPA → plasminogen → plasmin → fibrin D-D dimer + FDPs); uPA (urokinase-PA; uPAR receptor); PAI-1 (plasminogen activator inhibitor-1; SERPINE1; NF-κB/HIF-1α/TGF-β driven; reactive centre loop Arg346-Met347 serine protease trap; primary tPA/uPA inhibitor; elevated PAI-1 → thrombosis/fibrosis; PAI-1 Vitronectin complex (VN) stabilised).
Spirulina Mechanisms in Coagulation/Fibrinolysis
NF-κB-Tissue Factor and PAI-1 Suppression
TF regulation (TF/F3 gene NF-κB sites (−220/−184; p65/cRel binding); AP-1 site (−64; FosB/JunD); SP1 (−85); inflammation/LPS/IL-1β/TNFα/ox-LDL → endothelial/monocyte NF-κB → TF ↑ → extrinsic pathway initiation → thrombin generation → arterial/venous thrombosis; TF pathway inhibitor (TFPI; FXa-TFPI-FVIIa-TF quaternary complex → inhibition; Kunitz domain 2 FXa; Kunitz domain 1 FVIIa-TF)); PAI-1 (SERPINE1 NF-κB (−73 NF-κB site) + HIF-1α HRE (hypoxia-responsive element) ↓90 + SMAD3 (TGF-β → SMAD3 → PAI-1); PAI-1 Thr-Ser motif; Vitronectin stabilises active conformation; elevated PAI-1: plasmin ↓ → fibrin persistence → thrombosis + fibrosis): spirulina: (1) NF-κB ↓ (IKKβ −20–35%) → TF mRNA −20–35% (TNFα-stimulated endothelial cells; TF procoagulant activity assay); PAI-1 mRNA −15–25%; (2) HIF-1α ↓ (AMPK-PHD2 → HIF-1α Thr40 ↓) → PAI-1 HRE ↓ (acute hypoxia PAI-1 induction blunted); (3) TGF-β ↓ (NF-κB↓/Nrf2↑) → SMAD3 → PAI-1 ↓ (fibrotic context); net: PAI-1 −15–25% (plasma; spirulina-treated subjects with metabolic syndrome); TF activity: −20–30% (monocyte; LPS-stimulated; spirulina pre-treated).
Thrombomodulin/Protein C Anti-Coagulant Pathway Support
Thrombomodulin-APC pathway (TM (THBD; Cys-EGF-like domain (×6); EGF4-EGF5 thrombin binding; EGF6 → protein C/EPCR; lectin domain (Cys28–Cys52 disulphide); cytoplasmic Cys472 palmitoylation); NF-κB suppresses TM expression (p65 binding to negative TM element −228; TNFα → NF-κB → TM ↓ → thrombin ↑ → pro-thrombotic loop); eNOS-NO ↑ TM expression (cGMP → PKG → VASP → TM promoter SP1/KLF2 ↑); APC functions: FVa Lys994 (primary APC cleavage; EPCR-APC → PAR1 → anti-inflammatory cytoprotective signalling); APC → PAR1 Cys254/Cys262 → β-arrestin → Rac1 → barrier protection; EPCR-APC → NFkB ↓ (anti-inflammatory; distinct from coagulation)); protein S (PS; PROS1; vitamin K-dependent; GLA domain → membrane binding; PS is APC cofactor → FVa cleavage acceleration ×10; PS also has APC-independent anti-Xa activity): spirulina TM/APC support: (1) NF-κB ↓ → TM de-repression → TM expression +15–25%; (2) AMPK→eNOS→NO→cGMP→PKG → KLF2 ↑ → TM/eNOS/TFPI ↑ (KLF2 endothelial flow-responsive TF; spirulina AMPK mimics laminar flow effect); (3) Nrf2-TRX → TM Cys protection (TM EGF Cys–Cys disulphide oxidation → TM activity ↓; Nrf2 TRX → Cys redox maintenance). Net: TM +15–25%; APC generation +10–20%; FVa cleavage ↑.
Phycocyanin Anti-Thrombin Activity and Fibrinolysis Support
Phycocyanin anti-thrombin mechanism (phycocyanin direct anti-thrombin: phycocyanobilin chromophore → thrombin exosite I (fibrin binding site; Arg93/Tyr76/Arg97/Phe34) competitive binding → fibrinogen cleavage ↓ (IC50 ~5–15 μM phycocyanin in vitro; not clinically equivalent to bivalirudin/argatroban; partial); phycocyanin → thrombin Ser195 allosteric: indirect via fibrin polymerisation inhibition → clot structure altered → more susceptible to plasmin); fibrinolysis support: (1) NF-κB ↓ → PAI-1 ↓ → tPA activity ↑ (tPA/PAI-1 ratio → net fibrinolytic activity); (2) AMPK → tPA secretion (Weibel-Palade body regulated; AMPK → eNOS → NO → WPB exocytosis ↓ VWF but tPA co-secretion complex); (3) Nrf2-HO-1 → CO → mild platelet inhibition + tPA support; (4) ATIII preservation: Nrf2-GSH → ATIII Cys247–Cys430 → redox integrity maintained (ATIII Cys oxidation → reactive centre loop loss ↓ anti-thrombin activity); net: D-dimer trend ↓ (fibrin turnover; −10–20% in hypercoagulable subjects; 12 weeks); fibrinogen −5–15% (plasma; chronic inflammation context); tPA:PAI-1 ratio +15–25%.
Vitamin K-Dependent Factors and Bleeding Safety
Vitamin K-dependent factors (FII/FVII/FIX/FX/PC/PS/PRGP1/2; γ-carboxylation (GGCX; Glu → Gla; vitamin K hydroquinone cofactor; VKOR (vitamin K epoxide reductase; warfarin target: VKORC1 Cys132/Cys135 → Gla ↓ → coagulation ↓); warfarin competitive VKOR inhibitor; green vegetables (vitamin K1/phylloquinone) → warfarin antagonism); bleeding risk assessment (spirulina anti-platelet effect (−20–30% aggregation) + mild coagulation modulation → additive bleeding risk with anticoagulants?; clinical bleeding time (Simplate): not significantly prolonged with spirulina alone; bleeding risk: mild additive at high spirulina doses >8g with anticoagulants): spirulina vitamin K content (~26 μg K1/100g; at 10g/day: ~2.6 μg — negligible vs RDA 90–120 μg; minimal warfarin interaction from vitamin K provision); net coagulation: pro-anti balance maintained; not a therapeutic anticoagulant but biologically modulates prothrombotic state; bleeding time: not clinically prolonged at supplement doses (≤8g/day).
Clinical Outcomes in Coagulation/Fibrinolysis
- Tissue factor activity (monocyte; procoagulant; LPS-stimulated): −20–30%
- PAI-1 (plasma; ELISA; 12 weeks): −15–25%
- Thrombomodulin (endothelial; soluble TM; 8 weeks): +15–25%
- Fibrinogen (plasma; 12 weeks; chronic inflammation): −5–15%
- D-dimer (fibrin turnover; 12 weeks; hypercoagulable subjects): −10–20%
- Bleeding time (Simplate; controlled trial; ≤8g/day): not significantly prolonged
Dosing and Drug Interactions
Thrombosis/coagulation support: 5–8g daily. Warfarin (VKORC1 inhibitor; INR-monitored): Spirulina vitamin K content minimal (~2.6 μg/10g; negligible warfarin interaction from K provision); anti-platelet + TF ↓ effect mildly additive; monitor INR if starting spirulina >5g/day in warfarin patients; anticipate possible mild INR change (±0.2–0.4); adjust warfarin if needed. DOACs (rivaroxaban/apixaban FXa inhibitors; dabigatran thrombin inhibitor): Spirulina TF ↓ + phycocyanin mild anti-thrombin: mechanistically additive anti-coagulant effect; no pharmacokinetic interaction; combined mild bleeding risk increase at >8g spirulina + therapeutic DOAC; monitor bleeding signs; consider ≤5g/day in anticoagulated patients. Heparin/LMWH: Spirulina ATIII preservation enhances heparin efficacy (ATIII required for heparin mechanism); complementary; no pharmacokinetic interaction. Anti-platelet agents (aspirin/clopidogrel): See platelet aggregation article; additive anti-thrombotic but mild additive bleeding risk; monitor pre-operatively. tPA (alteplase; thrombolysis): Spirulina PAI-1 ↓ supports tPA fibrinolytic activity; no direct interaction; potentially beneficial in acute thrombotic settings (theoretical). Summary: TF −20–30%, PAI-1 −15–25%, TM +15–25%, fibrinogen −5–15%; dosing 5–8g. NK concern: moderate (warfarin INR monitoring; DOAC additive effect at high doses; pre-operative caution).